Inverness Counsel’s AstraZeneca AZN Stock Holding History

Inverness Counsel’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,500	Closed	-$350K	–	154
2020 Q4	$350K	Hold	3,500	–	–	0.01%	112
2020 Q3	$384K	Buy	+3,500	New	+$389K	0.02%	105

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Inverness Counsel's AZN Position: Q1 2021 in Review

Inverness Counsel sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 3,500 shares — an estimated $350K sold.

Inverness Counsel first reported a position in AZN in Q3 2020 and held it in 2 quarters. The position peaked at $384K in Q3 2020. 755 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Inverness Counsel reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Inverness Counsel sold 3,500 AstraZeneca shares in Q1 2021, an estimated $350K.
Inverness Counsel first reported a position in AstraZeneca in Q3 2020 and held it in 2 quarters.
Inverness Counsel's AstraZeneca position peaked at $384K in Q3 2020.
755 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Inverness Counsel's 13F filing for Q1 2021, filed 4 May 2021.